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summARy – The brain is no longer considered an immunoprivileged organ which is com-
pletely separated from the circulating immune cells by the blood-brain barrier and which shows 
a lowered or changed immunoreactivity. it has become clear that there are numerous interactions 
between the neurological, immune and neuroendocrinologic systems. The psychiatric disorder whi-
ch is supposed to be connected to changes in the functioning of the immune system is depression. 
one of the hypotheses suggesting the pathophysiology of depression is the cytokine hypothesis of 
depression. According to it, the behavior changes in depressed patients are a consequence of changes 
in cytokines. physiological and psychological effects of the immune activation during an infection, 
primarily mediated by central activity of peripherally excreted proinflammatory cytokines, are called 
“sickness behavior”. depression is connected with the activation of the inflammatory response sy-
stem. when it comes to the immune characteristics of depressive disorders, it should be stressed that 
depression is a heterogeneous disorder, so different types of depression can differ not only psychopa-
thologically but also at the immune level. depression is characterized by disorders in noradrenergic 
and serotonergic neurotransmission. proinflammatory cytokines are included in the noradrenergic 
and serotonergic neurotransmission in the brain areas that are thought to be involved in the patho-
genesis of depression. According to this model, depression can be considered a psychoneuroimmune 
disease in which the peripheral immune activation is responsible (by excreting the inflammatory 
mediator) for various behavioral, neuroendocrinologic and neurochemical changes connected to the 
psychiatric condition.
Key words: Cytokines; Major depressive disorder; Psychoneuroimmunology 
Correspondence to: Assist. Prof. Dalibor Karlović, MD, PhD, uni-
versity department of psychiatry, sestre milosrdnice university 
Hospital Center, vinogradska c. 29, HR-10000 Zagreb, Croatia
e-mail: dalibor.karlovic@gmail.com
Received october 24, 2011, accepted April 24, 2012
Introduction
from the perspective of psychoneuroimmunology, 
the brain is no longer considered an immunoprivileged 
organ which is completely separated from the circu-
lating immune cells by the blood-brain barrier and 
which shows a lowered or changed immunoreactivity. 
in the last decades, it has become clear that there are 
numerous interactions among the neurological, im-
mune and neuroendocrinologic systems. The concept 
of a two-way communication between the immune 
system and the central nervous system (Cns) has led 
to the question whether the immune system, besides 
its usual role, i.e. immune reaction, is included in neu-
ropathological processes. A psychiatric disorder that 
is supposed to be connected to changes in the func-
tioning of the immune system is depression. The dis-
turbed regulation of the immune system’s functional 
activity in depression is a phenomenon described on 
several occasions. depression is connected with the 
activation of the inflammatory response system. Ac-
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cording to this model, depression can be considered a 
psychoneuroimmune disease in which the peripheral 
immune activation is responsible (by excreting the 
inflammatory mediator) for various behavioral, neu-
roendocrinologic and neurochemical changes con-
nected to the psychiatric condition1,2.
The Cytokine Etiology of Depressive Disorders
one of the hypotheses suggesting the pathophysi-
ology of depression is the cytokine hypothesis of de-
pression. According to it, the behavior changes in 
depressed patients are a consequence of changes in 
cytokines3. The word cytokine comes from two words 
of greek origin: “cytos” meaning cell, and “kine” from 
the word “kinein” meaning to move. This term was in-
troduced so that a group of immunomodulatory mol-
ecules could be distinguished from the hematopoietic 
cell growth factors. Cytokines are polypeptides or 
glycopeptides with a low molecular mass of 6-70 kda 
excreted by macrophages due to their own function 
changing (autocrine effect) or the adjacent cell’s func-
tion (paracrine effect). Their creation is encouraged by 
the antigen-specific lymphocyte T4 activation. They 
behave as strong molecules which are released from 
the cells, transport themselves to other parts of the 
body, and influence other cells’ functions, which can 
lead to numerous biological effects. Their activity is 
closely connected to specific receptors that can be 
found in the cell and cell membrane4.
Cytokines are messengers which, along with hor-
mones and neurotransmitters, are very significant fac-
tors in the communication among human cells. They 
encompass a heterogeneous group of messenger mol-
ecules which synthesize immunocompetent cells such 
as lymphocytes and macrophages in order to regulate 
immune reactions. Cell activation and differentiation, 
chemotaxis and wide-spectrum cell proliferation are 
the effector functions of these proteins. The activity 
of cytokines depends on their concentration in the 
micro-environment and the expression strength of 
specific receptors on the surface of the target cell. in 
the human body, each live cell with a nucleus creates 
cytokines whose type and quantity of secretion de-
pend on the type and phase of cell differentiation and 
activation. They can be positive and negative regula-
tors of the immune response. They deliver information 
to the target cell which has the respective receptor. 
what occurs is gene activation with causal phenotypic 
or functional changes of the target cell. inhibitors can 
stop the cytokine synthesis and release by modulat-
ing their biological activity or by inhibiting the abil-
ity of the target cell to respond. Although their spe-
cific biological activities can vary, two main cytokine 
groups can be distinguished: inflammatory and anti-
inflammatory. The former group consists of cytokines 
directly or indirectly included into the inflammatory 
processes, such as interleukins il-1, il-6, interferon 
(inf-γ) and tumor necrosis factor (Tnf)-α. The lat-
ter group includes cytokines known for suppressing 
the immune response (il-4, il-10, il-13). Based on 
dominant biological activities, cytokines are divided 
into three basic groups5,6: i  mediators of innate im-
munity [proinflammatory cytokines (Tnf-α, il-1, 
il-6)], [interferon type i (inf-α, inf-β)], [Activa-
tors of nK and T cells (il-12, il-18)]; ii mediators 
of acquired immunity (il-2, inf-γ, il-4, il-5, il-
10 and Tgf-β); and iii stimulators of hematopoiesis 
[il-3 and factors of colony growth (gmCsf, gCsf, 
mCsf)].
This division corresponds to biological and struc-
tural differences as well as similarities of these media-
tors. The term interleukin is accepted and used for a 
group of mediators responsible for the communication 
between leukocytes. Today, 29 types of interleukins 
are known, i.e. il-1 to il-29. There are also more 
than 30 cytokines. many of them are growth factors, 
while some have an antiviral activity and are called 
interferons (inf). They regulate the growth and dif-
ferentiation of the immune system’s cells, of T and B 
lymphocytes and macrophages, but also the volume 
and length of inflammatory response. They modify 
the biological response and are interconnected into a 
cytokine regulation network. The increased cytokine 
excretion is not only linked to infections, but also to 
autoimmune and neurodegenerative diseases7,8. 
peripheral cytokine synthesis depends to a great 
extent on the activation state of the immune system. 
in pathological conditions, such as acute or chronic 
inflammation or tissue damage, the immune system 
is activated, while the activity of macrophages in-
creases, which contributes to the synthesis increase 
and cytokine excretion, e.g., il-1, il-6 and Tnf-α. 
Changes in cytokine synthesis on the periphery can 
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be caused by neuroendocrine influence on the immune 
system. Considering this, the activity of corticoster-
oids, which are synthesized in the adrenal cortex as 
the final product of the hypothalamic-pituitary-adre-
nal (HpA) axis, is most important. These hormones, 
especially cortisol, are included in the regulation of 
the immune response and cytokine synthesis. while 
low corticosteroid concentrations act on the synthe-
sis of inflammatory mediators in a stimulating way, 
high concentrations are immunosuppressive9-12. The 
neurotransmitters acetylcholine, dopamine, nora-
drenaline and serotonin are included in the functional 
status of the immune system as mediators through the 
influence on the hypothalamic corticotropin releasing 
factor (CRH) secretion. for example, while acetylcho-
line, dopamine, and noradrenaline have a stimulating 
effect on hypothalamic cells, serotonin suppresses the 
hypothalamic CRH secretion as well as the ACTH 
synthesis in the pituitary gland. 
Besides a somatic stress such as infection, chron-
ic inflammation, tissue damage, exposure to mental 
stress affects the synthesis of inflammatory mediators 
as well. Changes in the level of noradrenaline/sero-
tonin neurotransmission and the activity of the HpA 
axis are included in the synthesis of inflammatory me-
diators to a significant extent13. 
Cytokine Transport into the Central Nervous 
System
since the majority of cytokines are relatively big 
hydrophilic molecules, they do not pass through the 
blood-brain barrier under physiologic conditions. 
However, there are spots without the blood-brain bar-
rier (circumventricular region) or less restrictive areas 
like the organum vasculosum of the lamina terminalis 
and eminentia mediana, where a passive transport of 
cytokines from the blood to the brain parenchyma is 
possible. The integrity of the blood-brain barrier can 
be damaged by trauma or pathological conditions, 
which leads to the increased access of different in-
flammatory cells and molecules, including cytokines. 
moreover, cytokines can contribute to the damaging 
of the barrier and there is also a possibility for Tnf-α 
to lead to barrier degeneration. 
The mechanism of active transport could also be 
included in cytokine transfer through the barrier. Af-
ter entering the brain parenchyma, peripheral cytok-
ines bind to the corresponding receptors on the sur-
face of different cells including microglia, astrocytes 
and neurons. specific il-1, il-2 and Tnf-α recep-
tors were discovered on glial cells and hippocampus 
neurons. 
Besides passing through the blood-brain barrier, 
cytokines can bind to receptors on vascular endothe-
lial cells activating in such a manner the second mes-
senger; a direct mechanism of signalization in the 
Cns can thus be enabled.
Another possible indirect route to cytokine-medi-
ated communication of the immune system and brain 
is via vagus signalization. Afferent vagal fibers, which 
go from the immune system organs in which cytok-
ines are secreted, can enable a sensor input on the 
functional status of the immune system in the nucleus 
tractus solitarius, which is in medulla oblongata. 
Besides infiltration and indirect signalization 
from the periphery, cytokines (including il-6 and 
Tnf-α) and their receptors are synthesized by the 
brain, mainly in astrocytes and microglia. in certain 
circumstances, neurons are supposed to have the abil-
ity to secrete cytokines. Cytokine synthesis was found 
in several brain areas, including circumventricular re-
gion, hypothalamus, hippocampus, cerebellum, basal 
ganglia and nucleus of medulla oblongata. The role of 
central cytokine synthesis has not yet been clarified, 
so proinflammatory cytokines, including il-6 and 
Tnf-α, are considered to be contributing to neu-
rodevelopmental and neuroplastic processes, synapto-
genesis and tissue recovery14-18.
Besides positive effects, cytokines can have nega-
tive effects on the function of brain tissue, such as 
promoting neuronal impairment after stroke. fur-
thermore, cytokine synthesis in glial cells can be 
caused by antigenic impulses (virus infection), local 
or peripheral inflammatory reaction, or brain injuries. 
Cytokines are linked to the activity on monoamin-
ergic transmission. systemic administration of il-6 
was found to increase 5-HT neurotransmission in 
hippocampus, nucleus accumbens and frontal cortex, 
and it decreased the concentration of dopamine in nu-
cleus accumbens. neuroendocrine effects of periph-
eral and central proinflammatory cytokines, such as 
il-6, include the activation of the HpA axis, which is 
reflected by increased plasma concentrations of CRH, 
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vasopressin, ACTH and corticosteroids. Although 
proinflammatory cytokines are potent activators of 
the HpA axis, it should be stressed that in physiologi-
cal circumstances cytokines are able to stimulate the 
HpA axis to a certain extent because this neuroendo-
crine system’s activity is regulated by the inhibitory 
feedback mechanisms. The negative feedback mecha-
nism, which is characteristic of the HpA axis, stops its 
further stimulation with increased concentrations of 
corticosteroids. excessive stimulation of corticoster-
oid receptors in the hypothalamus and pituitary gland 
resulting from increased corticosteroid excretion 
causes decrease in the synthesis of CRH and ACTH, 
thus limiting the extent to which the HpA axis can be 
stimulated19,20.
The Phenomenon of “Sickness Behavior”
physiological and psychological effects of immune 
activation during an infection, primarily mediated by 
central activity of peripherally excreted proinflamma-
tory cytokines, are called “sickness behavior”21. sick-
ness behavior is accompanied by elevated temperature 
and various behavioral reactions, including decreased 
appetite, anorexia, weight loss, sleep disorders, psycho-
motor impairment, decreased interest in physical and 
social environment, libido loss, disorders of cognitive 
abilities, dysphoria, anhedonia and depressive mood. 
most of these reactions are hypothalamus-mediated. 
it seems that these behavioral changes are an expres-
sion of a centrally motivated condition which reorga-
nizes a sick person’s priorities in order to fight the in-
fectious agent22. However, not only has this behavior 
been seen during the infection, but also after systemic 
or central administration of cytokines. Chemotherapy, 
which often includes treatment with proinflamma-
tory and antivirus cytokines (il-2, Tnf-α, inf-α), 
is connected to depressive symptoms and symptoms 
similar to influenza, as well as cognitive disorders23. 
immunotherapy based on inf-α, which is often used 
in chronic hepatitis C therapy, is connected to symp-
toms of cognitive disorder, hopelessness, fatigue and 
depressive mood. The fact that symptoms of sickness 
behavior disappear almost instantly after the inter-
ruption of cytokine therapy supports the causal role of 
cytokines in the pathogenesis of this state24,25. 
The characteristics of the immune system activa-
tion in depressive disorder include an increase in the 
number of circulating lymphocytes and phagocytes, 
serum levels of the activated immune cell indicators, 
reduction in the levels of negative acute-phase pro-
teins, as well as increased secretion of proinflamma-
tory cytokines. Besides the cytokine hypothesis of 
depression, the increased plasma concentrations of 
proinflammatory cytokines (il-6) found in patients 
with depression seem to correlate with the severity of 
the psychiatric disorder and with activity measures of 
the HpA axis26.
furthermore, the centrally motivated state in-
duced by the activity of cytokines on the Cns can 
offer a probable explanation for the occurrence of vari-
ous behavioral, psychological and cognitive symptoms 
of depression. This thinking is supported by the ob-
servations of symptoms similar to depression in non-
depressed persons who receive cytokine therapy in the 
treatment of carcinoma and hepatitis C27,28.
depression can be considered a genetic disease, 
so the genetics of the immune system associated with 
depression was investigated. polymorphism of certain 
genes (e.g., the gene which codes Tnf-α) is consid-
ered to have greater predisposition for the develop-
ment of depressive disorder. 
Heterogeneity of Immune Characteristics of 
Depressive Disorders
when it comes to the immune characteristics of 
depressive disorders, it should be stressed out that 
depression is a heterogeneous disorder, so different 
types of depression can differ not only psychopatho-
logically but also at the immune level. many somatic 
disorders are accompanied by depression: acute and 
chronic infections, non-infectious conditions related 
to inflammations, for example, rheumatoid arthri-
tis, carcinoma, Alzheimer’s disease, multiple sclero-
sis and other neurodegenerative diseases. depressive 
symptomatology connected to other diseases does not 
necessarily have to be strictly a psychological reaction 
to pain, distress and inability associated with somatic 
diseases, but can be directly caused by the immune 
system activation and cytokine excretion. depressive 
symptoms accompanying the immune reaction can 
be alleviated by pretreatment with cytokine synthesis 
inhibitors and cytokine antagonists or by manipulat-
ing cytokine genes. most frequently, the side effects of 
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cytokine therapy that develop early in the treatment 
(usually within two weeks) include symptoms simi-
lar to influenza: fever, fatigue, headache, and myal-
gia. psychiatric side effects typically occur later in the 
treatment, within one to three months, and include 
dysphoria, anhedonia, anxiety, fatigue, anorexia, psy-
chomotor impairment and cognitive disorders. while 
the symptoms similar to influenza resolve with treat-
ment continuation, neuropsychiatric side effects can 
disappear only after therapy cessation or by including 
antidepressants29-31.
The Influence of Cytokines on Neurotransmitters
depression is characterized by disorders in nora-
drenergic and serotonergic neurotransmission. Hy-
pothetically speaking, the activation of the immune 
system can be causally linked with these disorders in 
signalization. proinflammatory cytokines are involved 
in the changes in noradrenergic and serotonergic neu-
rotransmission in the brain regions that are thought 
to be involved in the pathogenesis of depression (hy-
pothalamus, hippocampus, amygdala and prefrontal 
cortex), decreased activity of presynaptic 5-HT neu-
rons (a reflection of a decrease in 5-HT synthesis), 
changes in the 5-HT reuptake in the synaptic cleft 
as well as changes in postsynaptic 5-HT receptors. 
5-HT synthesis depends mainly on the availability of 
tryptophan precursors in the brain (and it has a com-
petitive relation with amino acids such as valine, leu-
cine and phenylalanine for the same cerebral transport 
mechanisms at the level of the blood-brain barrier). 
Cytokines reduce tryptophan availability by activat-
ing the enzyme which metabolizes it, indoleamine-
2,3-dioxygenase. such an excessive indoleamine-2,3-
dioxygenase stimulation can lead to a tryptophan 
decrease in serum, which is accompanied by a signifi-
cant reduction of 5-HT synthesis. low tryptophan 
availability in the brain can become the main event 
underlying the deficit of serotonin, which accompa-
nies depressive disorder32,33. The development and se-
verity of depressive symptoms, especially depressive 
mood, anorexia and concentration loss in patients re-
ceiving immunotherapy, correlate positively with the 
decrease in plasmatic concentrations of tryptophan 
during the treatment34. moreover, proinflammatory 
cytokines intensify the 5-HT transmission, which can 
lead to quick depletion of the reserves in the condi-
tions when the presynaptic 5-HT availability is low 
due to decreased 5-HT synthesis, caused by low tryp-
tophan availability. it has been observed that the oc-
currence of depressive and anxiety symptoms after the 
cytokine-induced stimulation of indoleamine-2,3-
dioxygenase can also result in intensified metabolite 
synthesis of indoleamine-2,3-dioxygenase, mediated 
by the kynurenine pathway, e.g., 3-hydroxykynure-
nine (3oHKyn) and quinolinic acid (Quin), neuro-
toxic substances involved in several neurodegenerative 
conditions, e.g., parkinson’s disease.  An intensified 
synthesis of these kynurenine metabolites has been 
noted in psychiatric anxious and depressive disorders. 
3oHKyn can cause increased monoamine oxidase 
(mAo) activity as well as the hyperproduction of 
free radicals that contain a reactive oxygen species 
(Ros) atom and are often linked to depression. The 
hyperproduction of free radicals can have a negative 
influence on the function and density of serotonergic 
and catecholaminergic receptors by inducing changes 
in membrane viscosity. what results from increased 
mAo activity is the lower concentration of 5-HT and 
catecholamine. in this way, besides direct decrease of 
5-HT availability, indoleamine-2,3-dioxygenase can 
contribute to monoaminergic disorders seen in depres-
sion in an indirect way. Besides presynaptic seroton-
ergic disorders, which can be linked to the increased 
indoleamine-2,3-dioxygenase activity, peripheral im-
mune activation can also be involved in the modifi-
cation of activities of transporters for 5-HT and/or 
the number and sensitivity of postsynaptic receptors 
(including 5-HT1A and 5-HT2A receptors). such 
changes can influence the 5-HT transmission and 
can cause serotonergic impoverishment in depressive 
disorder. The activation of radicals and exogenous ad-
ministration of proinflammatory cytokines can induce 
depressive symptomatology, partially even through 
the modulation of monoaminergic transmission35,36. 
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sažetak
pRegled psiHoneuRoimunološKiH spoZnAJA o eTiologiJi depResivniH poRemećAJA
B. Vidrih, D. Karlović, M. Bošnjak Pašić, M. Uremović, A. Kovak Mufić i A. Matošić
mozak se više ne smatra imunoprivilegiranim organom koji je potpuno odvojen od cirkulirajućih imunih stanica krvno 
moždanom barijerom i koji pokazuje smanjenu ili promijenjenu imunoreaktivnost. Jasno je da postoje brojne interakcije 
između neurološkog, imunog i neuroendokrinog sustava. psihijatrijski poremećaj za koji se pretpostavlja da je povezan s 
promjenama u funkcioniranju imunog sustava je depresija. Jedna od hipoteza koja objašnjava patofiziologiju depresije je 
citokina hipoteza; prema tom shvaćanju promjene ponašanja u depresivnih bolesnika posljedica su promjena u citokinima. 
fiziološki i psihološki učinci imune aktivacije tijekom infekcije, koji su primarno posredovani središnjim djelovanjem 
periferno izlučenih proupalnih citokina, jednim imenom nazivaju se “bolesnim osjećanjem”. depresija je povezana s akti-
viranjem sustava upalnog odgovora. u svezi s imunološkim značajkama depresije treba napomenuti da je depresija hetero-
geni poremećaj, što znači da različiti tipovi depresije mogu biti ne samo psihopatološki različiti, nego se jedni od drugih 
mogu razlikovati i na imunološkoj razini. depresija je obilježena poremećajima u noradrenergičnoj i serotoninergičnoj 
neurotransmisiji. proupalni citokini uključeni su u promjene u noradrenergičnoj i serotoninergičnoj neurotransmisiji u 
moždanim regijama za koje se misli da su uključene u patogenezu depresije.  prema tom modelu ona se može smatrati 
psihoneuroimunom bolešću u kojoj je periferna imuna aktivacija potaknuta lučenjem medijatora upale odgovorna za brojne 
ponašajne, neuroendokrine i neurokemijske promjene koje su povezane s psihijatrijskim stanjem. 
Ključne riječi: Citokini; Veliki depresivni poremećaj; Psihoneuroimunologija 

